Flagship Harbor Advisors LLC Sells 1,072 Shares of CVS Health Corporation $CVS

Flagship Harbor Advisors LLC trimmed its stake in shares of CVS Health Corporation (NYSE:CVS) by 3.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 30,321 shares of the pharmacy operator’s stock after selling 1,072 shares during the quarter. Flagship Harbor Advisors LLC’s holdings in CVS Health were worth $2,092,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Avion Wealth grew its position in CVS Health by 99.0% during the second quarter. Avion Wealth now owns 380 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 189 shares in the last quarter. Harbor Asset Planning Inc. purchased a new position in shares of CVS Health during the second quarter worth about $30,000. Bell Investment Advisors Inc grew its holdings in shares of CVS Health by 119.8% during the first quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator’s stock worth $31,000 after purchasing an additional 248 shares in the last quarter. Roxbury Financial LLC grew its holdings in shares of CVS Health by 78.3% during the second quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator’s stock worth $32,000 after purchasing an additional 202 shares in the last quarter. Finally, ORG Partners LLC grew its holdings in shares of CVS Health by 418.9% during the second quarter. ORG Partners LLC now owns 467 shares of the pharmacy operator’s stock worth $32,000 after purchasing an additional 377 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.

CVS Health Stock Performance

CVS Health stock opened at $80.80 on Thursday. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. The firm has a 50-day moving average of $76.25 and a 200-day moving average of $68.92. The firm has a market cap of $102.48 billion, a P/E ratio of 22.57, a P/E/G ratio of 0.91 and a beta of 0.60. CVS Health Corporation has a 1-year low of $43.56 and a 1-year high of $85.15.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.24. The company had revenue of $102.87 billion during the quarter, compared to analyst estimates of $98.85 billion. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. CVS Health’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Sell-side analysts expect that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be issued a $0.665 dividend. The ex-dividend date is Thursday, October 23rd. This represents a $2.66 annualized dividend and a yield of 3.3%. CVS Health’s dividend payout ratio (DPR) is 74.30%.

Insider Buying and Selling

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the sale, the director directly owned 22,156 shares in the company, valued at $1,573,519.12. This trade represents a 25.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 1.22% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

CVS has been the subject of several recent analyst reports. Truist Financial set a $92.00 price objective on CVS Health in a report on Tuesday, October 14th. Leerink Partners raised their price objective on CVS Health from $86.00 to $95.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Baird R W raised shares of CVS Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Robert W. Baird upgraded shares of CVS Health from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $71.00 to $82.00 in a research report on Thursday, August 14th. Finally, Wells Fargo & Company upped their price target on shares of CVS Health from $84.00 to $103.00 and gave the company an “overweight” rating in a research report on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and an average price target of $83.38.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.